FDA approves Global Blood Therapeutics' sickle cell pill

Global Blood Therapeutics has seen its sickle cell disease drug approved by the FDA, promising to be the first treatment targeting the root cause of the condition.

Q&A: Novartis’ Eric Hughes on transplantation

With approximately 3.2 million people worldwide living with end-stage renal disease, there is immense pressure on healthcare systems with long waiting lists for kidney and liver transplants

FDA cues up May verdict for Roche’s SMA challenger risdiplam

Novartis to buy The Medicines Company for $9.7bn

Novartis is to buy The Medicines Company and its cholesterol-lowering drug for $9.7 billion, confirming press speculation.

Takeda sets sights on first-line lung cancer market with new...

Investors look ahead to 2020 following briefings from pharma...

The great and the good of pharma and biotech descended on London to give investors updates on how their businesses are progressing at this year’s Jefferies conference, and provided insights